Fortress Biotech Inc. [NASDAQ: FBIO] jumped around 0.04 points on Monday, while shares priced at $5.48 at the close of the session, up 0.74%. The company report on April 7, 2021 that Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference.
Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the 20th Annual Needham Virtual Healthcare Conference, taking place April 12-15, 2021. The company will present on Monday, April 12, 2021, at 4:30 p.m. ET and will also participate in one-on-one meetings during the conference. A webcast of the company’s presentation will be available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the presentation.
About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company that was ranked in Deloitte’s 2019 and 2020 Technology Fast 500™, annual rankings of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children’s Research Hospital and Nationwide Children’s Hospital. For more information, visit www.fortressbiotech.com.
Fortress Biotech Inc. stock is now 72.87% up from its year-to-date (YTD) trading value. FBIO Stock saw the intraday high of $6.10 and lowest of $5.06 per share. The company’s 52-week high price is 5.78, which means current price is +77.35% above from all time high which was touched on 04/12/21.
Compared to the average trading volume of 1.43M shares, FBIO reached a trading volume of 15587624 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Fortress Biotech Inc. [FBIO]?
The Benchmark Company have made an estimate for Fortress Biotech Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on October 02, 2020. While these analysts kept the previous recommendation, B. Riley FBR raised their target price to Buy. The new note on the price target was released on December 18, 2019, representing the official price target for Fortress Biotech Inc. stock. Previously, the target price had yet another raise to $10, while B. Riley FBR Inc. analysts kept a Buy rating on FBIO stock.
The Average True Range (ATR) for Fortress Biotech Inc. is set at 0.45, with the Price to Sales ratio for FBIO stock in the period of the last 12 months amounting to 10.23. The Price to Book ratio for the last quarter was 4.35.
How has FBIO stock performed recently?
Fortress Biotech Inc. [FBIO] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.10. With this latest performance, FBIO shares gained by 23.98% in over the last four-week period, additionally plugging by 23.15% over the last 6 months – not to mention a rise of 171.29% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for FBIO stock in for the last two-week period is set at 73.64, with the RSI for the last a single of trading hit 81.56, and the three-weeks RSI is set at 68.69 for Fortress Biotech Inc. [FBIO]. The present Moving Average for the last 50 days of trading for this stock 4.01, while it was recorded at 4.84 for the last single week of trading, and 3.37 for the last 200 days.
Fortress Biotech Inc. [FBIO]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Fortress Biotech Inc. [FBIO] shares currently have an operating margin of -206.74 and a Gross Margin at +62.99. Fortress Biotech Inc.’s Net Margin is presently recorded at -102.03.
Return on Total Capital for FBIO is now -40.68, given the latest momentum, and Return on Invested Capital for the company is -30.05. Return on Equity for this stock declined to -73.53, with Return on Assets sitting at -16.76. When it comes to the capital structure of this company, Fortress Biotech Inc. [FBIO] has a Total Debt to Total Equity ratio set at 83.49. Additionally, FBIO Total Debt to Total Capital is recorded at 45.50, with Total Debt to Total Assets ending up at 25.48. Long-Term Debt to Equity for the company is recorded at 81.65, with the Long-Term Debt to Total Capital now at 44.50.
Reflecting on the efficiency of the workforce at the company, Fortress Biotech Inc. [FBIO] managed to generate an average of -$419,153 per employee. Receivables Turnover for the company is 2.64 with a Total Asset Turnover recorded at a value of 0.16.Fortress Biotech Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.40 and a Current Ratio set at 5.50.
Earnings analysis for Fortress Biotech Inc. [FBIO]
With the latest financial reports released by the company, Fortress Biotech Inc. posted -0.19/share EPS, while the average EPS was predicted by analysts to be reported at -0.23/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 17.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for FBIO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Fortress Biotech Inc. go to 25.50%.
Insider trade positions for Fortress Biotech Inc. [FBIO]
There are presently around $175 million, or 34.50% of FBIO stock, in the hands of institutional investors. The top three institutional holders of FBIO stocks are: NANTAHALA CAPITAL MANAGEMENT, LLC with ownership of 8,680,909, which is approximately 5.544% of the company’s market cap and around 28.72% of the total institutional ownership; BLACKROCK INC., holding 4,719,280 shares of the stock with an approximate value of $25.86 million in FBIO stocks shares; and VANGUARD GROUP INC, currently with $25.03 million in FBIO stock with ownership of nearly 39.64% of the company’s market capitalization.
Positions in Fortress Biotech Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 50 institutional holders increased their position in Fortress Biotech Inc. [NASDAQ:FBIO] by around 3,258,541 shares. Additionally, 31 investors decreased positions by around 2,155,868 shares, while 15 investors held positions by with 26,500,573 shares. The mentioned changes placed institutional holdings at 31,914,982 shares, according to the latest SEC report filing. FBIO stock had 20 new institutional investments in for a total of 708,915 shares, while 9 institutional investors sold positions of 160,847 shares during the same period.